
Customize View
Recently disclosed strategic alliances only (within the last two years)
Include Strategic Alliances for:Current subsidiaries



Strategic Alliances

Recently Disclosed Strategic Alliances
Strategic Alliance Name
Company Name
Primary Industry
Source
Abbott Laboratories (NYSE:ABT)
Sanofi (ENXTPA:SAN)
Health Care Equipment
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Absci Corporation (NasdaqGS:ABSI)
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentClient Announcements Jan-10-2019
Business Description: Absci Corporation operates as a generative AI drug creation company in the United States. Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Abzena Limited
Bioverativ USA Inc.
Life Sciences Tools and Services
Abzena Limited - Form Doc
Business Description: Abzena Limited provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. The company provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs. In addition, the company provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. The company was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom. As of October 11, 2018, Abzena Limited was taken private.
Adimab, LLC
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: Adimab, LLC operates as a biotech company that develops an integrated yeast-based antibody discovery, maturation, and biomanufacturing platform. The company discovers and develops bispecific antibodies. It focuses on IgG, ScFv, and CD3-based bispecific antibodies. The company was founded in 2007 and is based in Lebanon, New Hampshire.
Aimmune Therapeutics, Inc.
Sanofi Biotechnology SAS
Biotechnology
Aimmune Therapeutics, Inc. 2020 Form 10-K
Business Description: Aimmune Therapeutics, Inc., a biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead characterized oral desensitization immunotherapy (CODIT) product candidate is Palforzia, used for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate that is in a Phase II clinical trial for the treatment of egg allergy in pediatric and young adult patients, and other CODIT product candidates targeting food allergies, such as cow’s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics and a clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study PALFORZIA with adjunctive dupilumab in peanut-allergic patients. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Aimmune Therapeutics, Inc. operates as a subsidiary of Société des Produits Nestlé S.A.
Alibaba Health Information Technology Limited (SEHK:241)
Sanofi (ENXTPA:SAN)
Drug Retail
Alibaba Health Information Technology Limited (SEHK:241) 2020 Form Doc
Business Description: Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, adult and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and traditional Chinese medicine through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, AMap, Freshippo, DingTalk, and Quark. In addition, it engages in the digital tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2022 Form 20-F
Business Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Amagma, Inc.
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Key DevelopmentClient Announcements Jan-18-2022
Business Description: Amagma, Inc. develops antibody therapies to treat inflammatory diseases. The company’s antibody discovery and optimization strategies target domains of enzymes and block their activity. Amagma, Inc. was incorporated in 2019 and is based in Waltham, Massachusetts.
Aqemia SAS
Sanofi (ENXTPA:SAN)
Health Care Technology
Key DevelopmentStrategic Alliances Jun-15-2022
Business Description: Aqemia SAS develops drug discovery software that predicts the affinity between drug candidates and therapeutic targets responsible for diseases. The company was founded in 2019 and is based in Paris, France.
Arovella Therapeutics Limited (ASX:ALA)
Sanofi-Aventis Groupe S.A.
Pharmaceuticals
Arovella Therapeutics Limited (ASX:ALA) 2020 Form Doc
Business Description: Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Carlton, Australia.
Ascentage Pharma Group International (SEHK:6855)
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Innovent Biologics, Inc. (SEHK:1801) 2023 Form Doc
Business Description: Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. It also has APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449, an oral bioavailable inhibitor of FAK, ROS1, and ALK tyrosine kinases; APG-5918, an orally available and selective EED inhibitor; APG-265, a MDM2 protein degrade; and UBX1967/1325. In, addition it engages in medical research and development; venture capital investment; and rental services. The company has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
AstraZeneca PLC (LSE:AZN)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Biocorp Production (ENXTPA:ALCOR)
Sanofi (ENXTPA:SAN)
Health Care Equipment
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Biocorp Production designs, develops, and manufactures medical devices in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of prefilled syringes; BIOPASS, a reconstitution system with a needle; Sween, a device that provides real assistance in the administration of medication and closure systems. The company was incorporated in 2004 and is headquartered in Issoire, France. As of August 4, 2023, Biocorp Production operates as a subsidiary of Novo Nordisk A/S.
BioMed X GmbH
Sanofi (ENXTPA:SAN)
Life Sciences Tools and Services
Key DevelopmentStrategic Alliances Oct-24-2022
Business Description: BioMed X GmbH offers biomedical research in the fields of oncology, immunology, neuroscience, and platform technologies. The company was incorporated in 2013 and is based in Heidelberg, Germany.
Biomedical Advanced Research And Development Authority
Sanofi (ENXTPA:SAN)
Diversified Support Services
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Biomedical Advanced Research And Development Authority is headquartered in the United States.
bioMérieux S.A. (ENXTPA:BIM)
Sanofi (ENXTPA:SAN)
Health Care Equipment
bioMérieux S.A. (ENXTPA:BIM) 2019 Form Doc
Business Description: bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Biontech Rna Pharmaceuticals Gmbh
Sanofi (ENXTPA:SAN)
Research and Consulting Services
BioNTech SE (NasdaqGS:BNTX) 2020 Form F-1
Business Description: Biontech Rna Pharmaceuticals Gmbh was formerly known as Ribological GmbH. The company is based in Mainz, Germany.
BioNTech SE (NasdaqGS:BNTX)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Blackstone Inc. (NYSE:BX)
Sanofi (ENXTPA:SAN)
Asset Management and Custody Banks
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services. The real estate segment specializes in opportunistic, core+ investments as well as debt investment opportunities collateralized by commercial real estate, and stabilized income-oriented commercial real estate across North America, Europe and Asia. The firm’s corporate private equity business pursues transactions throughout the world across a variety of transaction types, including large buyouts,special situations, distressed mortgage loans, mid-cap buyouts, buy and build platforms, which involves multiple acquisitions behind a single management team and platform, and growth equity/development projects involving significant majority stakes in portfolio companies and minority investments in operating companies, shipping, real estate, corporate or consumer loans, and alternative energy greenfield development projects in energy and power, property, dislocated markets, shipping opportunities, financial institution breakups, re-insurance, and improving freight mobility, financial services, healthcare, life sciences, infrastructure, enterprise tech and consumer, as well as consumer technologies. The firm considers investment in Asia and Latin America. It has a three year investment period. Its hedge fund business manages a broad range of commingled and customized fund solutions and its credit business focuses on loans, and securities of non-investment grade companies spread across the capital structure including senior debt, subordinated debt, preferred stock and common equity. Blackstone Inc. was founded in 1985 and is headquartered in New York, New York with additional offices across Asia, Europe and North America.
Bolt Biotherapeutics, Inc. (NasdaqGS:BOLT)
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
BridgeBio Pharma, Inc. (NasdaqGS:BBIO)
Maze Therapeutics, Inc.
Biotechnology
Key DevelopmentStrategic Alliances Dec-07-2020
Business Description: BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Bukwang Pharmaceutical Co., Ltd. (KOSE:A003000)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Bukwang Pharmaceutical Co., Ltd. (KOSE:A003000) - Form 
Business Description: Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson’s disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
CareDx, Inc (NasdaqGM:CDNA)
Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN)
Biotechnology
Key DevelopmentStrategic Alliances Oct-19-2021
Business Description: CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Curia Global, Inc.
Translate Bio, Inc.
Life Sciences Tools and Services
Key DevelopmentStrategic Alliances Sep-12-2019
Business Description: Curia Global, Inc. operates as a contract research, development, and manufacturing organization. The company discovers and develops an active pharmaceutical ingredient (API); and develops a messenger RNA (mRNA) solution to streamline the development and delivery of mRNA-based products. It offers custom API manufacturing, fermentation, finished dosage form, high potency, lipid nanoparticle, rare/orphan, stability and release testing, sterile fill finish, APIs and intermediates catalog, and fine chemicals catalog. The company offers analytical testing services, batch release and stability lot testing, extractables and leachable, method development and validation, package and device testing, and solid-state chemistry lab testing services. It also offers intellectual property litigation support, intellectual property services, regulatory support, quality assurance, and sterile university consultative services. The company offers products and services from research and development through commercial manufacturing to pharmaceutical and biopharmaceutical customers. The company was formerly known as AMRI and changed its name to Curia Global, Inc. in July 2021. Curia Global, Inc. was founded in 1991 and is headquartered in Albany, New York.
Daiichi Sankyo Company, Limited (TSE:4568)
Sanofi K.K.
Pharmaceuticals
Key DevelopmentClient Announcements Mar-31-2021
Business Description: Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Denali Therapeutics Inc. (NasdaqGS:DNLI)
Genzyme Corporation Inc
Biotechnology
Denali Therapeutics Inc. (NasdaqGS:DNLI) 2020 Form 10-K
Business Description: Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer’s disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc. (NasdaqGS:DNLI)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer’s disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
eGENESIS, INC.
Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN)
Biotechnology
Key DevelopmentStrategic Alliances Jan-09-2023
Business Description: eGENESIS, INC., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also offers development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. eGENESIS, INC. has a research collaboration with the University of Miami Leonard M. Miller School of Medicine. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.
Eli Lilly and Company (NYSE:LLY)
Innovent Biologics, Inc. (SEHK:1801)
Pharmaceuticals
Innovent Biologics, Inc. (SEHK:1801) 2023 Form Doc
Business Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company (NYSE:LLY)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Faes Farma, S.A. (BME:FAE)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Faes Farma, S.A. (BME:FAE) - Form 
Business Description: Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN)
Sanofi SA
Biotechnology
Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) 2020 Form 424B4
Business Description: Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Genomic Health, Inc.
Aventis Inc.
Biotechnology
Genomic Health, Inc. 2018 Form 10-K
Business Description: Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California. As of November 8, 2019, Genomic Health, Inc. operates as a subsidiary of Exact Sciences Corporation
GlaxoSmithKline Pharmaceuticals Limited (BSE:500660)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited (BSE:500660) - Form Doc
Business Description: GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of Shingles and Post herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; TENOVATE and Flutivate for skin conditions to reduce inflammation; PHYSIOGEL for dry skin and dry skin associated with redness and itch; Zimig for fungal skin infections; COBADEX CZS, a multivitamin; and Supacef, a bactericidal cephalosporin antibiotic. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Google LLC
Sanofi (ENXTPA:SAN)
Interactive Media and Services
Key DevelopmentStrategic Alliances Jun-18-2019
Business Description: Google LLC develops technology products and provides services to organize the information. It offers a range of products and platforms, such as Search, Maps, Ads, Gmail, Android, Chrome, and YouTube. The company was founded in 1998 and is headquartered in Mountain View, California. Google LLC operates as a subsidiary of Alphabet Inc.
GSK plc (LSE:GSK)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
H2, Inc.
Sanofi (ENXTPA:SAN)
Health Care Technology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: H2, Inc. designs and develops a cloud-based health management platform that tracks blood sugar readings and related activities. It offers a mobile application that allows patients to manage blood glucose. The company’s platform also allows health professionals to view patient's latest blood glucose readings and related activities. In addition, it sells a smart cable to sync data from glucose meters to smartphones through other online retailers in Taiwan and the United States. The company was founded in 2013 and is based in Taipei, Taiwan.
Hanmi Pharm. Co., Ltd. (KOSE:A128940)
Innovent Biologics, Inc. (SEHK:1801)
Pharmaceuticals
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
HBM Holdings Limited (SEHK:2142)
Kiadis Pharma N.V.
Biotechnology
Key DevelopmentStrategic Alliances Aug-19-2020
Business Description: HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9378 for the treatment of Asthma; and HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People’s Republic of China.
Huagong Tech Company Limited (SZSE:000988)
Sanofi SA
Electronic Equipment and Instruments
Huagong Tech Company Limited (SZSE:000988) - Form 
Business Description: Huagong Tech Company Limited manufactures and sells laser equipment, optical communication devices, laser holographic anti-counterfeiting products, and sensors and information tracing in China and internationally. The company offers laser smart equipment, such as laser marking, laser cutting, laser surface treatment, laser welding, and plasma cutting equipment, as well as specialized equipment; and hologram products, including hologram stickers, hot stamping foils, security hologram, packing hologram, metalized paper, and barcode products. It also provides optical communication transceivers; automotive electronic products; PTC motor starting thermistors; NTC series temperature sensors; and PTC series thermistors, heating components and devices, heaters, and heating chips. In addition, the company offers omni-channel marketing management systems; traceability systems; smart agriculture products; government traceability and supervision platform; WMS and intelligent logistics distribution systems; data acquisition systems; and transferring and laminating films, and cold stamping foils. Huagong Tech Company Limited was founded in 1999 and is headquartered in Wuhan, China.
Hutchison MediPharma Limited
Innovent Biologics (Suzhou) Co., Ltd
Pharmaceuticals
Key DevelopmentStrategic Alliances Nov-30-2018
Business Description: Hutchison MediPharma Limited, a drug development company, focuses on discovering, developing, and commercializing therapeutics for oncology and autoimmune diseases. Its product portfolio includes HMPL-004, an oral botanical product that acts on multiple targets in the pathogenesis of inflammatory bowel disease; HMPL-504/AZD6094 (Volitinib), a potent ATP-competitive c-Met inhibitor for renal, gastric, and non-small cell lung cancer, as well as others with c-Met deregulation; Fruquintinib (HMPL-013), a small molecule compound that inhibits vascular endothelial growth factor (VEGF) receptors; and Sulfatinib (HMPL-012), a small molecule that inhibits the tyrosine kinase activity associated with VEGF and fibroblast growth factor receptors. The company’s products also comprise Epitinib (HMPL-813), an orally active small molecule inhibitor that targets the epithelial growth factor receptor (EGFR); Theliatinib (HMPL-309), an inhibitor of EGFR tyrosine kinase; Selective Syk inhibitor (HMPL-523), a small molecule spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis, as well as other autoimmune and inflammatory diseases; and Selective FGFR inhibitor (HMPL-453), a small molecule FGFR inhibitor for the treatment of small cell lung, breast, gastric, and bladder cancers, as well as multiple myeloma. It has compounds in pre-clinical, phase I, phase II, and phase III development in the United States, Europe, Australia, and China. Hutchison MediPharma Limited has strategic partnerships with AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono, and Nestlé Health Science. The company was founded in 2002 and is based in Shanghai, China. Hutchison MediPharma Limited operates as a subsidiary of Hutchison China MediTech Ltd.
HUTCHMED (China) Limited (AIM:HCM)
Innovent Biologics (Suzhou) Co., Ltd
Pharmaceuticals
HUTCHMED (China) Limited (AIM:HCM) 2021 Form 20-F
Business Description: HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kδ (phosphoinositide 3’-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton’s tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Immune Design Corp.
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2016 Form 20-F
Business Description: Immune Design Corp., a clinical-stage immunotherapy company, focuses on cancer with in vivo approaches to enable the body’s immune system to fight disease. The company develops products based on its ZVex and GLAAS discovery platforms. Its lead product candidate is G100, a monotherapy and combination therapy that is in Phase II clinical trials for treating patients with follicular non-Hodgkin lymphoma. The company has collaboration and license agreements with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck Sharp & Dohme Corp. As of April 2, 2019, Immune Design Corp. operates as a subsidiary of Merck & Co., Inc.
Immunext, Inc.
Sanofi (ENXTPA:SAN)
Research and Consulting Services
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Immunext, Inc. operates as a research and consulting services company. It was founded in 2012 and is based in Lebanon, New Hampshire.
Immunocore Holdings plc (NasdaqGS:IMCR)
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentStrategic Alliances Jun-03-2022
Business Description: Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Incyte Biosciences International S.à r.l.
Innovent Biologics (HK) Limited

Key DevelopmentClient Announcements Dec-16-2018
Business Description: Incyte Biosciences International S.à r.l. operates as a subsidiary of Incyte Corporation.
Innate Pharma S.A. (ENXTPA:IPH)
Sanofi SA
Biotechnology
Innate Pharma S.A. (ENXTPA:IPH) 2020 Form 20-F
Business Description: Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Innovent Biologics, Inc. (SEHK:1801)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kδ; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.
Kowa Company, Ltd.
Sanofi K.K.
Pharmaceuticals
Key DevelopmentClient Announcements Oct-30-2012
Business Description: Kowa Company, Ltd. engages in health and medical, general trading, optics and electronics, hospitality, foods, and real estate businesses. The company researches, develops, and manufactures OTC drugs, healthcare products, dietary supplements, drinks, and ethical drugs, as well as medical equipment, such as ophthalmological instruments, IOL, etc. It also provides prominar/spotting scopes, binoculars, panoramic telescopes, industrial optical products, LED lighting fixtures, LED lamps, professional video equipment, and renewable energy power generation systems. In addition, the company engages in the manufacture, import/export, and wholesale of products ranging from food ingredients to processed foods, as well as is involved in mansion and house development, and residential renting activities. Further, the company engages in general trading of various items, such as pharmaceutical ingredients, ingredients for cosmetics, monomers and specialty chemicals, oil and fats, feed additives, iodine and their compounds, lithium and their compounds, activated carbon and coal, marine products, food and beverages, industrial machinery and equipment, vessels, thermal power station, direct current supply systems, ceramic tiles, natural stone or exterior products, etc. Additionally, it manufactures and markets/sells textiles, apparel, and fashion goods/finishing goods, as well as engages in branding activities. The company also manages two hotels in Nagoya. The company was formerly known as Kofuku Sangyo Co., Ltd. and changed its name to Kowa Company, Ltd. in 1960. Kowa Company, Ltd. was founded in 1894 and is headquartered in Nagoya, Japan.
Kymera Therapeutics, Inc. (NasdaqGM:KYMR)
Genzyme Corporation Inc
Biotechnology
Kymera Therapeutics, Inc. (NasdaqGM:KYMR) 2021 Form 10-K
Business Description: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. (NasdaqGM:KYMR)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Laekna Therapeutics Shanghai Co., Ltd.
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: Laekna Therapeutics Shanghai Co., Ltd. is a gene therapy company, which develops therapeutics for oncology and metabolic diseases. It develops pre-clinical discovery programs for oncology and liver diseases. It develops small molecule candidate LAE001 (previously known as CFG920) for prostate cancer. The company was founded in 2016 and is based in Shanghai, China.
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)
Bioverativ Inc.
Pharmaceuticals
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) 2019 Form 10-K
Business Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.
Lonza Group AG (SWX:LONN)
Sanofi (ENXTPA:SAN)
Life Sciences Tools and Services
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
MAB Discovery GmbH
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentClient Announcements Dec-14-2015
Business Description: MAB Discovery GmbH discovers and develops monoclonal antibody therapeutics. The company has a strategic alliance with BioDuro Biologics. MAB Discovery GmbH was founded in 2010 and is based in Neuried, Germany. Mab Discovery Gmbh offers basic research, applied research, and experimental development services for biotechnology industry. The company was incorporated in 2010 and is based in Polling, Germany.
MannKind Corporation (NasdaqGM:MNKD)
Sanofi SA
Biotechnology
MannKind Corporation (NasdaqGM:MNKD) 2015 Form 10-K
Business Description: MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corporation (NasdaqGM:MNKD)
Sanofi-Aventis U.S. LLC
Biotechnology
MannKind Corporation (NasdaqGM:MNKD) 2018 Form 10-K
Business Description: MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MedImmune, LLC
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2018 Form 20-F
Business Description: MedImmune, LLC operates a biologics research and development company that researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity, cardiovascular and metabolic diseases; oncology; neuroscience; and infection and vaccines. The company offers Synagis palivizumab, a monoclonal antibody to prevent serious lower respiratory tract diseases; IMFINZI, a human monoclonal antibody product for the treatment of patients with locally advanced and metastatic urothelial carcinoma; FluMist Quadrivalent Influenza Vaccine Live, Intranasal, a quadrivalent influenza vaccine; Trivalent FluMist T/LAIV, a live attenuated influenza vaccine; and MEDI8897, an extended half-life respiratory syncytial virus RSV F monoclonal antibody mAb used for the prevention of lower respiratory tract infection caused by RSV. The company was incorporated in 1987 and is based in Gaithersburg, Maryland. As of June 5, 2007, MedImmune, LLC operates as a subsidiary of AstraZeneca PLC
MedImmune, LLC
Sanofi Pasteur SA
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: MedImmune, LLC operates a biologics research and development company that researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity, cardiovascular and metabolic diseases; oncology; neuroscience; and infection and vaccines. The company offers Synagis palivizumab, a monoclonal antibody to prevent serious lower respiratory tract diseases; IMFINZI, a human monoclonal antibody product for the treatment of patients with locally advanced and metastatic urothelial carcinoma; FluMist Quadrivalent Influenza Vaccine Live, Intranasal, a quadrivalent influenza vaccine; Trivalent FluMist T/LAIV, a live attenuated influenza vaccine; and MEDI8897, an extended half-life respiratory syncytial virus RSV F monoclonal antibody mAb used for the prevention of lower respiratory tract infection caused by RSV. The company was incorporated in 1987 and is based in Gaithersburg, Maryland. As of June 5, 2007, MedImmune, LLC operates as a subsidiary of AstraZeneca PLC
Meiji Seika Pharma Co., Ltd
Kadmon Holdings, Inc. (NasdaqGS:KDMN)
Pharmaceuticals
Kadmon Holdings, Inc. (NasdaqGS:KDMN) 2021 Form 10-K
Business Description: Meiji Seika Pharma Co., Ltd engages in the manufacture and sale of ethical pharmaceuticals, agricultural chemicals, and veterinary drugs in Japan and internationally. The company offers ethical pharmaceuticals, including antibacterial drugs, and specialty and generic pharmaceuticals; agricultural chemicals under the ORZYEMATE and ZAXA names; and livestock and fishery veterinary drugs, and nutritional supplements. It has a research collaboration agreement with TWOCELLS. The company was formerly known as Meiji Seika Kaisha Ltd and changed its name to Meiji Seika Pharma Co., Ltd on April 1, 2011. Meiji Seika Pharma Co., Ltd was founded in 1916 and is headquartered in Tokyo, Japan.
Merck & Co., Inc. (NYSE:MRK)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck Serono GmbH
Ablynx NV
Pharmaceuticals
Key DevelopmentClient Announcements Oct-03-2013
Business Description: Merck Serono GmbH manufactures and distributes bio-pharmaceuticals and small molecule products. It offers medicines to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The company was founded in 1906 and is based in Darmstadt, Germany. Merck Serono GmbH operates as a subsidiary of MERCK Kommanditgesellschaft auf Aktien.
MINAPHARM Pharmaceuticals (CASE:MIPH)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
MINAPHARM Pharmaceuticals (CASE:MIPH) - Form 
Business Description: MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules. The company offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinarytract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy. The company was founded in 1958 and is headquartered in Cairo, Egypt.
Mirati Therapeutics, Inc. (NasdaqGS:MRTX)
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentClient Announcements Oct-07-2021
Business Description: Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
miRecule, Inc.
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: miRecule, Inc. operates as a biotechnology company that develops microRNA-based drug discovery platform to address challenges in cancer therapy. It offers miRecule’s DREAmiR, a that platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease and then create an RNA therapeutic that can directly target and fix that genetic abnormality. The company’s product also integrates genomic sequencing, expression, and prognostic data from hundreds of cancer patients with high throughput screening data of microRNA that can be used to identify microRNA candidates for miR replacement therapy. The company’s therapeutics programs include Facioscapulohumeral Muscular Dystrophy (FSHD) and Head & Neck Squamous Cell Carcinoma (HNSCC). miRecule, Inc. was founded in 2016 and is based in Gaithersburg, Maryland.
Mochida Pharmaceutical Co., Ltd. (TSE:4534)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Mochida Pharmaceutical Co., Ltd. (TSE:4534) - Form Doc
Business Description: Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension. In addition, the company provides Atelec to treat calcium channel blocker with a long-acting hypotensive effect; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Heparin Sodium MOCHIDA, an anticoagulant agent; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Dinagest, a therapeutic agent for endometriosis, adenomyosis, and dysmenorrhea. Further it offers skin care, baby care, personal care, and nursing products. Additionally, the company develops mesalazine, ethyl icosapentate, daridorexant, dotinurad, and treprostinil drugs for the treatment of ulcerative colitis, hypertriglyceridemia, insomnia, gout and hyperuricemia, and pulmonary hypertension associated with interstitial lung disease; and dMD-001, a medical device that is used for the treatment of articular cartilage lesions, as well as dMD-002, which is used for the treatment of cavernous nerve injury. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Nanjing IASO Biotherapeutics
Innovent Biologics, Inc. (SEHK:1801)
Biotechnology
Key DevelopmentClient Announcements Jan-10-2022
Business Description: Nanjing IASO Biotherapeutics, a biopharmaceutical company, discovers and develops cell therapies for oncology and autoimmune diseases. It develops autologous and allogeneic CAR-T and biologics product candidates, including CT103A, an anti-BCMA CAR-T cell therapy under pivotal study for relapsed/refractory multiple myeloma; and a therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company also provides CD19/CD22, a dual-targeted chimeric antigen receptor CAR-T cell therapy for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL). Nanjing IASO Biotherapeutics was founded in 2017 and is based in Nanjing, China. It has additional offices in Shanghai, China; and San Jose, California.
National Institutes of Health
Sanofi (ENXTPA:SAN)
Life Sciences Tools and Services
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: National Institutes of Health operates as a medical research agency in the United States. It offers services for conducting and supporting basic, clinical, and translational medical research; and investigates the causes, treatments, and cures for common and rare diseases. The company also provides leadership and direction to programs designed to improve the health by conducting and supporting research in the causes, diagnosis, prevention, and cure of human diseases; in the processes of human growth and development; in the biological effects of environmental contaminants; in the understanding of mental, addictive, and physical disorders; and in directing programs for the collection, dissemination, and exchange of information in medicine and health. In addition, it supports the research of non-federal scientists in universities, medical schools, hospitals, and research institutions in the United States and internationally; and provides training for research investigators. National Institutes of Health was formerly known as Laboratory of Hygiene and changed its name to National Institutes of Health in 1930. National Institutes of Health was founded in 1887 and is headquartered in Bethesda, Maryland with locations in Poolesville, Baltimore, Frederick, and Rockville, Maryland; and Hamilton, Montana.
NeuroVive Pharmaceutical Asia, Inc.
Sanofi-Aventis Korea Co., Ltd.
Life Sciences Tools and Services
Abliva AB (publ) (OM:ABLI) 2019 Form Doc
Business Description: NeuroVive Pharmaceutical Asia, Inc. researches and develops pharmaceuticals, under license of parent company. The company is based in Taiwan. NeuroVive Pharmaceutical Asia, Inc. operates as a subsidiary of NeuroVive Pharmaceutical AB.
Nurix Therapeutics, Inc. (NasdaqGM:NRIX)
Genzyme Corporation Inc
Biotechnology
Nurix Therapeutics, Inc. (NasdaqGM:NRIX) 2021 Form 10-K
Business Description: Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Owkin, Inc.
Sanofi (ENXTPA:SAN)
Health Care Technology
Sanofi (ENXTPA:SAN) 2022 Form 20-F
Business Description: Owkin, Inc. operates as an artificial intelligence company that develops software solutions for medical research. It offers its machine-learning algorithms across a broad network of academic medical centers. The company was incorporated in 2016 and is based in New York, New York with additional offices in Boston, Massachusetts; London, United Kingdom; Nantes and Paris, France; and Geneva, Switzerland.
Oxford Biomedica plc (LSE:OXB)
Sanofi (ENXTPA:SAN)
Biotechnology
Oxford Biomedica plc (LSE:OXB) - Form Doc
Business Description: Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
PeptiDream Inc. (TSE:4587)
Sanofi SA
Biotechnology
PeptiDream Inc. (TSE:4587) - Form 
Business Description: PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
Pharming Group N.V. (ENXTAM:PHARM)
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentStrategic Alliances Jan-04-2022
Business Description: Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Precigen, Inc. (NasdaqGS:PGEN)
Provention Bio, Inc.
Biotechnology
Provention Bio, Inc. 2023 Form 10-K
Business Description: Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Provention Bio, Inc.
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey. As of April 27, 2023, Provention Bio, Inc. operates as a subsidiary of Sanofi.
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX)
Genzyme Corporation Inc
Biotechnology
Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) 2021 Form S-1
Business Description: Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Revolution Medicines, Inc. (NasdaqGS:RVMD)
Genzyme Corporation Inc
Biotechnology
Revolution Medicines, Inc. (NasdaqGS:RVMD) 2021 Form 10-K
Business Description: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Roche Holding AG (SWX:ROG)
Innovent Biologics (HK) Limited
Pharmaceuticals
Key DevelopmentStrategic Alliances Jun-08-2020
Business Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG (SWX:ROG)
Innovent Biologics, Inc. (SEHK:1801)
Pharmaceuticals
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Roche Holding AG (SWX:ROG)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Royalty Pharma plc (NasdaqGS:RPRX)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Royalty Pharma plc (NasdaqGS:RPRX) 2020 Form S-1
Business Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc (NasdaqGS:RPRX)
Sanofi US Services Inc.
Pharmaceuticals
Royalty Pharma plc (NasdaqGS:RPRX) 2020 Form S-1
Business Description: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
S.C. Medimfarm S.A.
Sanofi (ENXTPA:SAN)
Health Care Distributors
S.C. Medimfarm S.A. - Form 
Business Description: S.C. MEDIMFARM S.A. engages in the wholesale and retail of pharmaceuticals and cosmetics. It is involved in the supply, storage, conservation, monitoring, and forecasting of medicines and cosmetics. The company offers its products through agents and partners. S.C. MEDIMFARM S.A. was founded in 1991 and is based in Ploiesti, Romania.
Salipro Biotech AB
Sanofi (ENXTPA:SAN)
Biotechnology
Key DevelopmentStrategic Alliances Nov-08-2022
Business Description: Salipro Biotech AB develops a nano-membrane technology that stabilizes membrane proteins. The company is based in Stockholm, Sweden.
Sangamo Therapeutics, Inc. (NasdaqGS:SGMO)
Genzyme Corporation Inc
Biotechnology
Sangamo Therapeutics, Inc. (NasdaqGS:SGMO) 2020 Form 10-K
Business Description: Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Sanofi (ENXTPA:SAN)
Innovent Biologics, Inc. (SEHK:1801)
Pharmaceuticals
Innovent Biologics, Inc. (SEHK:1801) 2023 Form Doc
Business Description: Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Sanofi Pasteur Inc.
Translate Bio MA, Inc
Pharmaceuticals
Translate Bio, Inc. 2020 Form 10-Q
Business Description: Sanofi Pasteur Inc. produces vaccines. The company offers influenza and pediatric vaccines, as well as polio injectable vaccines. Sanofi Pasteur Inc. was formerly known as Aventis Pasteur Inc. and changed its name to Sanofi Pasteur Inc. in January 2005. The company was incorporated in 1977 and is based in Swiftwater, Pennsylvania. Sanofi Pasteur Inc. operates as a subsidiary of Sanofi.
Sanofi Pasteur Inc.
Translate Bio, Inc.
Pharmaceuticals
Key DevelopmentStrategic Alliances Jun-07-2021
Business Description: Sanofi Pasteur Inc. produces vaccines. The company offers influenza and pediatric vaccines, as well as polio injectable vaccines. Sanofi Pasteur Inc. was formerly known as Aventis Pasteur Inc. and changed its name to Sanofi Pasteur Inc. in January 2005. The company was incorporated in 1977 and is based in Swiftwater, Pennsylvania. Sanofi Pasteur Inc. operates as a subsidiary of Sanofi.
Sanofi Pasteur SA
Translate Bio, Inc.
Pharmaceuticals
Key DevelopmentStrategic Alliances Oct-15-2020
Business Description: Sanofi Pasteur SA engages in the development, production, and distribution of human vaccines for public health, medical, and scientific communities. Sanofi Pasteur SA was formerly known as Aventis Pasteur S.A. and changed its name to Sanofi Pasteur SA in 2004. The company was incorporated in 1989 and is based in Lyon, France with operations in France and internationally. Sanofi Pasteur SA operates as a subsidiary of Sanofi.
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SASE:2070)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SASE:2070) - Form 
Business Description: Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia. The company is also involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics, as well as engages in wholesale and retail of medicines and related products. It operates and maintains healthcare facilities. In addition, the company engages in the research and development of medical science activities. The company was founded in 1986 and is based in Buraydah, the Kingdom of Saudi Arabia.
Schrödinger, Inc. (NasdaqGS:SDGR)
Sanofi (ENXTPA:SAN)
Health Care Technology
Schrödinger, Inc. (NasdaqGS:SDGR) 2021 Form 10-K
Business Description: Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Seagen Inc. (NasdaqGS:SGEN)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607)
Sanofi (ENXTPA:SAN)
Health Care Distributors
Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) 2020 Form Doc
Business Description: Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including anti-tumor, heart and cerebral vessels, psychoneural, anti-infection, auto-immunity, digestive tract and metabolism, and respiratory system. It provides approximately 700 varieties of drugs. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores, and online drug business. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China.
Shionogi & Co., Ltd. (TSE:4507)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Shionogi & Co., Ltd. (TSE:4507) - Form Doc
Business Description: Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay, an anti-HIV drug. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, and Refractory/unexplained chronic cough; Zuranolone for Depression; SDT-001, Inattentive ADHD pediatric; BPN14770 for Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamous cell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
SK Chemicals Co.,Ltd (KOSE:A285130)
Sanofi (ENXTPA:SAN)
Commodity Chemicals
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: SK Chemicals Co., Ltd. provides chemicals and life sciences products and solutions in South Korea and internationally. The company develops copolysters, coating and adhesive materials, engineering plastics, prepergs, bio materials, and 3D printing materials, as well as specialty chemicals, pharmaceutical products, and vaccines. It has a collaborate agreement with Standigm, Inc. to develop an AI-driven drug candidate for non-alcoholic steatohepatitis. The company was founded in 1969 and is headquartered in Seongnam, South Korea.
Société des Industries Pharmaceutiques de Tunisie - S.A. (BVMT:SIPHA)
Sanofi (ENXTPA:SAN)
Pharmaceuticals
Société des Industries Pharmaceutiques de Tunisie - S.A. (BVMT:SIPHA) - Form 
Business Description: Société des Industries Pharmaceutiques de Tunisie - S.A. engages in the research, development, manufacture, packaging, and marketing of pharmaceutical products for human use in Tunisia and internationally. The company offers products in the areas of allergology, analgesics, anesthesia, antihypertensive, antispasmodics, cardiology and angiology, cardiovascular system, dermatology, gastroenterology, hepatology, infectiology, metabolism and nutrition, neurology, pneumology, rheumatology, and stomatology, as well as anti-inflammatory drugs. It produces drugs of various galenic formulations in the form of tablets, capsules, sachets, tubes, suppositories, drinkable phials, perfusable bags, flasks, litters of concentrated solutions, perfusable solution bottles, and injectable ampoules. Société des Industries Pharmaceutiques de Tunisie - S.A. was founded in 1970 and is headquartered in Ben Arous, Tunisia.
Stanford University
Sanofi (ENXTPA:SAN)
Education Services
Key DevelopmentStrategic Alliances May-06-2021
Business Description: Stanford University is an educational and research institution that provides academic programs in sciences and interdisciplinary areas. The university offers graduate, undergraduate, executive, professional, continuing, and K-12 education. It focuses on areas such as earth sciences, engineering, humanities and sciences, business, education, law, and medicine. The university also provides research facilities that include Center for Advanced Study in the Behavioral Sciences, National Bureau of Economic Research, Stanford Linear Accelerator Center, Woods Institute for the Environment, Freeman Spogli Institute for International Studies, and Stanford Institute for Creativity and the Arts. Stanford University was founded in 1885 and is based in Stanford, California.
Stanford University School of Medicine
Sanofi (ENXTPA:SAN)
Education Services
Sanofi (ENXTPA:SAN) 2022 Form 20-F
Business Description: Stanford University School of Medicine provides clinical care, research, and education services. The institution was founded in 1956 and is based in Stanford, California. Stanford University School of Medicine operates as a subsidiary of Stanford University.
Surface Logix, Inc. (Acquired)
Kadmon Corporation, LLC
Pharmaceuticals
Kadmon Holdings, Inc. (NasdaqGS:KDMN) 2021 Form 10-K
Business Description: As of April 12, 2011, Surface Logix, Inc. was acquired by Nano-Terra, Inc. Surface Logix, Inc., a drug development company, creates and develops small molecule drugs to treat metabolic and cardiovascular diseases. It offers new chemical entities that target tissues and organ systems. The company’s small molecule drugs also target the gastrointestinal tract or the cardiovascular systems. In addition, it offers various programs in the areas of metabolic, cardiovascular, and other diseases. Surface Logix, Inc. was incorporated in 1999 and is headquartered in Brighton, Massachusetts.
Swedish Orphan Biovitrum AB (publ) (OM:SOBI)
Sanofi (ENXTPA:SAN)
Biotechnology
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
The University of Texas M. D. Anderson Cancer Center
Innovent Biologics, Inc. (SEHK:1801)
Health Care Facilities
Innovent Biologics, Inc. (SEHK:1801) 2022 Form Doc
Business Description: The University of Texas M. D. Anderson Cancer Center operates a healthcare specialty center, which provides cancer patient care, research, education, and prevention services. The company offers prevention and screening, including breast cancer screening, cervical cancer screening, colorectal cancer screening exams, endometrial cancer screening exams, liver cancer screening exams, lung cancer screening exams, mobile mammography, ovarian cancer screening exams, prostate cancer screening exams, skin cancer screening exams, women's screening exams, and men's screening exams; cancer research services in the areas of basic science, translational research, clinical research, and prevention and personalized risk assessment; clinical trials to test new treatments for both common and rare cancers; and research-driven cancer care and comprehensive educational programs that include undergraduate degrees, professional education, clinical and research training, and advanced nursing education to enable the next generation to join the fight to end cancer. The company has strategic collaboration with Federation Bio to design and manufacture a synthetic microbial consortium immunotherapy to treat cancer patients. The University of Texas M. D. Anderson Cancer Center was formerly known as The University of Texas System Cancer Center and changed its name to The University of Texas M. D. Anderson Cancer Center in 1988. The company was founded in 1941 and is based in Houston, Texas with additional locations in Conroe, League City, and Sugar Land, Texas. The University of Texas M. D. Anderson Cancer Center operates as a subsidiary of The University of Texas System.
Translate Bio MA, Inc
Sanofi Pasteur Inc.

Translate Bio, Inc. 2020 Form 10-Q
Business Description: Translate Bio MA, Inc operates as a subsidiary of Translate Bio, Inc. (NasdaqGS:TBIO).
Translate Bio, Inc.
Sanofi Pasteur Inc.
Biotechnology
Translate Bio, Inc. 2021 Form 10-K
Business Description: Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. As of September 13, 2021, Translate Bio, Inc. operates as a subsidiary of Sanofi.
TrialSpark, Inc.
Sanofi (ENXTPA:SAN)
Health Care Technology
Key DevelopmentStrategic Alliances Oct-04-2022
Business Description: TrialSpark, Inc. owns and operates a platform that provides clinical trial sites with medication, monetary compensation, study visits, and study-related tests and procedures. The company’s platform enables trial design and completion. The company’s platform allows life science, biotechnology, and digital health companies to run tech-backed clinical trials. It serves doctors, sites, and individuals. The company was incorporated in 2013 and is based in New York, New York.
U.S. Department of Health and Human Services
Sanofi (ENXTPA:SAN)
Diversified Support Services
Sanofi (ENXTPA:SAN) 2023 Form 20-F
Business Description: U.S. Department of Health and Human Services is a diversified support services company. It is based in Washington, District of Columbia.
UCB SA (ENXTBR:UCB)
Sanofi SA
Pharmaceuticals
UCB SA (ENXTBR:UCB) - Form Doc
Business Description: UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer’s disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Yakult Honsha Co.,Ltd. (TSE:2267)
Sanofi K.K.
Packaged Foods and Meats
Yakult Honsha Co.,Ltd. (TSE:2267) - Form Doc
Business Description: Yakult Honsha Co.,Ltd. manufactures and sells food and beverage products in Japan, the Americas, Asia, Oceania, and Europe. The company operates through Food and Beverages (Japan), Food and Beverages (The Americas), Food and Beverages (Asia and Oceania), Food and Beverages (Europe), Pharmaceuticals, and Others segments. It offers fermented milk drinks, juices, noodles, etc. through its home delivery and retail store channels. The company also provides pharmaceutical products, such as Elplat, an antineoplastic drug, as well as anticancer drugs and other pharmaceuticals. In addition, it offers cosmetics; and operates the Tokyo Yakult Swallows, a professional baseball team. The company was founded in 1935 and is headquartered in Tokyo, Japan.
*denotes proprietary relationship